The diagnosis and treatment of dyskeratosis congenita: A review

Journal of Blood Medicine

Volumn 5, Issue , 2014, Pages 157-167

  Fernández García, M Soledad ^a,b   Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Clinical; Diagnosis; Dyskeratosis congenita; Genetics; Treatment

Indexed keywords

ANDROGEN; CYCLOSPORIN; DYSKERIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXYMETHOLONE; RAP1 PROTEIN; RIBONUCLEOPROTEIN; SIRTUIN; SIRTUIN 6; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW DEPRESSION; CANCER RISK; CHEMORADIOTHERAPY; DNA DEGRADATION; DYSKERATOSIS CONGENITA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INHERITANCE; LEUKOPLAKIA; LIVER DISEASE; LUNG FIBROSIS; NAIL DYSTROPHY; PHENOTYPE; PLURIPOTENT STEM CELL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SKIN PIGMENTATION; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA; VIRILIZATION;

EID: 84930908011     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S47437     Document Type: Review

References (52)

1. Bohn OL, Whitten J, Spitzer B, et al. Posttransplant lymphoprolifera-tive disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita. Int J Surg Pathol. 2013;21(5): 520-525.
2. Mason PJ, Bessler M. The genetics of dyskeratosis congenita. Cancer Genet. 2011;204(12):635-645.
3. Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res. 2012;730(1-2):43-51.
4. Alder JK, Parry EM, Yegnasubramanian S, et al. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat. 2013;34(11):1481-1485.
5. Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010;92(3):419-424.
6. Islam A, Rafiq S, Kirwan M, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol. 2013;162(6):854-856.
7. Alcaraz-Perez F, Garcia-Castillo J, Garcia-Moreno D, et al. A non-canonical function of telomerase RNA in the regulation of developmental myelopoiesis in zebrafish. Nat Commun. 2014;5:3228.
8. Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int J Hematol. 2013;97(1):20-29.
9. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-186.
10. Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita. EJHG. 2011;19(11):1-11.
11. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009; 361(24):2353-2365.
12. Sinha S, Trivedi V, Krishna A, Rao N. Dyskeratosis congenita-management and review of complications: a case report. Oman Med J. 2013;28(4):281-284
13. Beier F, Foronda M, Martinez P, Blasco MA. Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita. Blood. 2012;120(15):2990-3000.
14. Karunakaran A, Ravindran R, Arshad M, Ram MK, Laxmi MK. Dyskeratosis congenita: a report of two cases. Case Rep Dent. 2013;2013:845125.
15. Finzi A, Morara M, Pichi F, Veronese C, Ciardella AP. Vitreous hemorrhage secondary to retinal vasculopathy in a patient with dyskeratosis congenita. Int Ophthalmol. Epub October 10, 2013.
16. Khincha PP, Savage SA. Genomic characterization of the inherited bone marrow failure syndromes. Semin Hematol. 2013;50(4):333-347.
17. Leguit RJ, van den Tweel JG. The pathology of bone marrow failure. Histopathology. 2010;57(5):655-670.
18. Nickels EM, Soodalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol. 2013;4(4): 254-269.
19. Gramatges MM, Bertuch AA. Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res. 2013;162(6):353-363.
20. Parry EM, Alder JK, Lee SS, et al. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet. 2011;48(5):327-333.
21. Batista LF, Artandi SE. Understanding telomere diseases through analysis of patient-derived iPS cells. Curr Opin Genet Dev. 2013;23(5): 526-533.
22. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11(3):161-176.
23. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer. 2002;2(8):627-633.
24. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8(6):450-458.
25. Deng Z, Glousker G, Molczan A, et al. Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome. Proc Natl Acad Sci U S A. 2013;110(36): E3408-E3416.
26. Carrillo J, Gonzalez A, Manguan-Garcia C, Pintado-Berninches L, Perona R. p53 pathway activation by telomere attrition in X-DC primary fibroblasts occurs in the absence of ribosome biogenesis failure and as a consequence of DNA damage. Clin Transl Oncol. 2014;16(6): 529-538.
27. Gadalla SM, Savage SA. Telomere biology in hematopoiesis and stem cell transplantation. Blood Rev. 2011;25(6):261-269.
28. Perez-Rivero G, Ruiz-Torres MP, Diez-Marques ML, et al. Telomerase deficiency promotes oxidative stress by reducing catalase activity. Free Radic Biol Med. 2008;45(9):1243-1251.
29. Walne AJ, Bhagat T, Kirwan M, et al. Mutations in the telomere capping complex in bone marrow failure and related syndromes. Haematologica. 2013;98(3):334-338.
30. Kirwan M, Beswick R, Walne AJ, et al. Dyskeratosis congenita and the DNA damage response. Br J Haematol. 2011;153(5):634-643.
31. Parry EM, Alder JK, Qi X, Chen JJ, Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607-5611.
32. Shtessel L, Ahmed S. Telomere dysfunction in human bone marrow failure syndromes. Nucleus. 2011;2(1):24-29.
33. Keller RB, Gagne KE, Usmani GN, et al. CTC1 Mutations in a patient with dyskeratosis congenita. Pediatr Blood Cancer. 2012;59(2):311-314.
34. Faure G, Revy P, Schertzer M, Londono-Vallejo A, Callebaut I. The C-terminal extension of human RTEL1, mutated in Hoyeraal-Hreidarsson syndrome, contains Harmonin-N-like domains. Proteins. 2014;82(6):897-903.
35. Walne AJ, Vulliamy T, Kirwan M, Plagnol V Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am J Hum Genet. 2013;92(3):448-453.
36. Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telom-erase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102(44): 15960-15964.
37. Vulliamy TJ, Dokal I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie. 2008;90(1):122-130.
38. Savage S., Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet Med. 2010;12(12):753-764.
39. Ballew BJ, Yeager M, Jacobs K, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum Genet. 2013;132(4):473-480.
40. Savage S. Dyskeratosis congenita. In: Pagon R, Adam M, Ardinger H, et al, editors. Dyskeratosis Congenita. Seattle, WA: University of Washington, Seattle; 2013.
41. Ayas M, Nassar A, Hamidieh AA, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant. 2013;48(9):1168-1172.
42. Gadalla SM, Sales-Bonfim C, Carreras J, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis con-genita. Biol Blood Marrow Transplant. 2013;19(8):1238-1243.
43. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8(3):167-179.
44. Neumann AA, Reddel RR. Telomere maintenance and cancer-look, no telomerase. Nat Rev Cancer. 2002;2(11):879-884.
45. Lieberman L, Dror Y. Advances in understanding the genetic basis for bone-marrow failure. Curr Opin Pediatr. 2006;18(1):15-21.
46. Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165(3):349-357.
47. Colita A, Tanase A, Varady Z, Colita AD, Arion C. Fludarabine, low-dose cyclophosphamide and rabbit antithymocyte globulin allowed stable engraftment after allogeneic peripheral blood stem cell transplantation for poly-transfused dyskeratosis congenita patient: case report. Transplant Proc. 2013;45(7):2849-2853.
48. Kharfan-Dabaja MA, Otrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Bone Marrow Transplant. 2012;47(9):1254-1255.
49. Isoda T, Mitsuiki N, Ohkawa T, et al. Irreversible leukoencephalopa-thy after reduced-intensity stem cell transplantation in a dyskeratosis congenita patient with TINF2 mutation. J Pediatr Hematol Oncol. 2013;35(4):e178-;182.
50. Pereboeva L, Westin E, Patel T, et al. DNA damage responses and oxidative stress in dyskeratosis congenita. PloS one. 2013;8(10): e76473.
51. Serravallo M, Jagdeo J, Glick SA, Siegel DM, Brody NI. Sirtuins in dermatology: applications for future research and therapeutics. Arch Dermatol Res. 2013;305(4):269-282.
52. Agarwal S, Loh YH, McLoughlin EM, et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010;464(7286):292-296.